The effect of growth hormone releasing hormone 
In 1982, the predicted presence of growth hormone releasing hormone (GHRH) was confirmed when it was isolated from two patients with pancreatic islet cell adenomas (1, 2) . Subsequently, two major forms of GHRH have been found to be present in the human hypothalamus and are identical to the 1-40 and 1-44 amino acid peptides isolated from the human pancreatic islet cell adenomas (3) . Since the discovery of GHRH, rapid development and evaluation of this peptide in human volunteer studies have resulted in the following information, (i) It is estimated that 75% of all children with growth hormone deficiency have GHRH deficiency rather than GH deficiency with intact and responsive pituitary glands (4) . (ii) Chronic GHRH administration in growth hormone deficient children has been shown to be an effective and well tolerated therapy for normalizing growth velocity (5) . It is classically accepted that GH deficiency is characterized by increased insulin sensiti¬ vity, whereas GH excess and/or GH treatment causes insulin resistance (6) . (10) . [6,6- A number of studies have evaluated the effects of GH administration to normal human subjects (6) 
